Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Extensive research

Video game company for the long run

Remedy Entertainment
Download report (PDF)

Remedy has progressed as planned in all its strategic objectives since the IPO a year ago. The gaming projects have progressed as scheduled, and Remedy has advanced successfully to the simultaneous development of two large scale gaming projects. The company has a good relationship with two strong publishers, with whom we believe the co-operation has gone well thus far. Although the progress of the strategy does not yet reflect in the company’s numbers due to the developmental stage of the projects, the development going as planned has substantially decreased Remedy’s risk level when compared to last year. We expect the multi- project model strategy transition currently underway to start to bear fruit next year. We reiterate our buy recommendation and increase our target price to 8.50 EUR (previously 7.5 EUR).

Login required

This content is only available for logged in users

Create account

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures03.06.2018

201718e19e
Revenue17.220.931.2
growth-%4.6 %21.5 %49.6 %
EBIT (adj.)2.6-0.07.7
EBIT-% (adj.)15.0 %-0.2 %24.7 %
EPS (adj.)0.16-0.010.50
Dividend0.000.000.20
Dividend %1.7 %
P/E (adj.)40.3neg.24.1
EV/EBITDA25.8759.715.0

Forum discussions

Insider purchases have been made. The homegrown feel has been broken, and an international CEO has been recruited. Former Chairman and principal...
16 hours ago
16
Now this latest Dev Diary has been released. It reveals more gameplay and looks good. Bigger investments in this area. It has allowed for more...
18 hours ago
by Henkka
14
A little Easter surprise there. It would indeed be great if these were purchased with personal funds, as the announcements seem to indicate....
21 hours ago
by Manajo
14
At first glance, these seem to be shares bought with their own money. They appeared twice in Kauppalehti, 4128 shares for the CEO and 890 shares...
22 hours ago
by NukkeNukuttaja
16
They’re taking a bit of a risk with this April Fool’s joke, aren’t they? “Dates behind bars” = release date. I’m guessing most people will miss...
yesterday
21
Pian…
yesterday
by Aruzo
25
Yesterday, I met with Remedy’s new CEO, primarily to explain how our Hesuli works and what investors currently think about Remedy. Overall, ...
4/1/2026, 9:48 AM
by Atte Riikola
74
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.